• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Trifluoromethylbenzenes

Research Briefing on Benzonitrile, 4-isocyanato-3-methyl-2-(trifluoromethyl)- (CAS: 627531-79-7) in Chemical Biology and Pharmaceutical Applications

The compound Benzonitrile, 4-isocyanato-3-methyl-2-(trifluoromethyl)- (CAS: 627531-79-7) has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique structural features and potential applications in drug discovery. This briefing synthesizes the latest findings regarding this compound, focusing on its synthesis, reactivity, and biological relevance.

Recent studies have highlighted the compound's utility as a versatile building block in medicinal chemistry. The presence of both isocyanate and trifluoromethyl groups makes it particularly valuable for creating diverse molecular architectures. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its effectiveness in synthesizing novel kinase inhibitors, with the trifluoromethyl group enhancing both binding affinity and metabolic stability.

In terms of synthetic applications, researchers have developed improved methods for handling this compound, addressing previous challenges with its stability. A notable advancement comes from a 2024 Nature Protocols paper describing a room-temperature stable formulation that maintains reactivity while reducing decomposition risks. This development has significantly expanded its practical utility in combinatorial chemistry approaches.

The compound's mechanism of action has been elucidated through several structural biology studies. X-ray crystallography data reveals that the isocyanate group forms stable covalent bonds with nucleophilic residues in target proteins, while the trifluoromethyl group contributes to hydrophobic interactions. This dual functionality makes it particularly valuable for targeting cysteine-rich proteins, as demonstrated in recent work on SARS-CoV-2 main protease inhibitors.

From a safety and toxicology perspective, new in vitro studies have provided important insights. Research published in Chemical Research in Toxicology (2024) indicates that while the compound shows moderate cytotoxicity at high concentrations, its risk profile is manageable with proper handling protocols. These findings support its continued use in pharmaceutical development with appropriate safety measures.

Looking forward, several research groups are exploring the compound's potential in targeted protein degradation strategies. Preliminary results suggest that derivatives of 627531-79-7 could serve as effective warheads in PROTAC molecules, opening new avenues for drug discovery against challenging targets. This application represents one of the most promising directions for future research involving this compound.

The pharmaceutical industry has shown growing interest in this compound, with at least three major companies including it in their fragment-based drug discovery programs. Its combination of synthetic accessibility and biological relevance positions it as a valuable tool for addressing emerging therapeutic challenges, particularly in oncology and infectious disease research.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)